In animal models, an EGFR inhibitor, gefitinib, prevents carcinogenesis of gallbladder and lung cancer (Kiguchi et al, 2005; Yan et al, 2006), and reduces the incidence of metastasis of prostate carcinoma cells (Angelucci et al, 2006). Here, EGFR is linked to lung cancer.